micro-community-banner
  • Saved

2yr
Clinical Characteristics Associated With Secondary Generalization in Patients With Ocular Myasthenia Gravis: a Systematic Review and Meta-Analysis

Clinical Characteristics Associated With Secondary Generalization in Patients With Ocular Myasthenia Gravis: a Systematic Review and Meta-Analysis

Source : https://n.neurology.org/content/101/16/e1594

Background and Objectives Ocular myasthenia gravis (OMG) is an autoimmune disorder resulting in ocular symptoms such as diplopia and ptosis. The proportion of patients who convert to secondary generalized myasthenia...

Risk factors such as female sex and anti-AChR positivity have been identified to have possible associations with SGMG, but there are not enough quality observational studies. There is a need for a prospective global database of patients with OMG, including all countries with different populations.

  • Saved

2yr
Effect of efgartigimod on Muscle Group Subdomains in Participants With Generalized Myasthenia Gravis: Post Hoc Analyses of the Phase 3 Pivotal ADAPT Study

Effect of efgartigimod on Muscle Group Subdomains in Participants With Generalized Myasthenia Gravis: Post Hoc Analyses of the Phase 3 Pivotal ADAPT Study

Source : https://pubmed.ncbi.nlm.nih.gov/37843174/

These post hoc analyses of MG-ADL and QMG subdomain data from ADAPT suggest that efgartigimod is beneficial in improving muscle function and strength across all muscle groups, leading to the...

These findings confirm that efgartigimod can improve function and strength across all muscle groups involved in the symptomatology of gMG, with potential implications in reducing disease burden in patients affected by weakness in these subdomains. The data also support the benefit efgartigimod offers across MG-ADL and QMG subdomains and in a...

  • Saved

2yr
Symptoms of Myasthenia Gravis Obscured by Old Age and Unilateral Presentation

Symptoms of Myasthenia Gravis Obscured by Old Age and Unilateral Presentation

Source : https://www.cureus.com/articles/161865-symptoms-of-myasthenia-gravis-obscured-by-old-age-and-unilateral-presentation

Myasthenia gravis (MG) is a neuromuscular junction disorder involving autoantibodies affecting the postsynaptic muscle membrane. We report an 81-year-old man who presented to the emergency department with three days of...

This case demonstrated some of the many difficulties in identifying new onset MG in older patients. When examining older patients for dysarthria or facial droop, it can be helpful to establish a baseline with either family or by using recent images. Identifying MG in older patients can also be difficult because of high incidences of...

  • Saved

2yr
Serum Metabolomics of Treatment Response in Myasthenia Gravis

Serum Metabolomics of Treatment Response in Myasthenia Gravis

Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0287654

Objective High-dose prednisone use, lasting several months or longer, is the primary initial therapy for myasthenia gravis (MG). Upwards of a third of patients do not respond to treatment. Currently...

A now-defined metabolomic and lipidomic profile can undergo validation as a treatment predictive marker for MG patients undergoing corticosteroid therapy. Metabolomic profiles of outcome measures had limited overlap consistent with their assessing distinct aspects of treatment response and supporting unique biological underpinning for each...

  • Saved

2yr
Summary of the Immunoglobulin National Society (IgNS) 12th National Conference

Thought of as the premier conference in the immunoglobulin and biologics space, the bustling Immunoglobulin National Society (IgNS) 12th national conference took place at the Sheraton Denver Downtown from Oct. 5 to 8, 2023. 

The four-day meeting welcomed more than 1,200 attendees who had access to more than 50 clinical and business sessions. Educational programs, keynote speakers, exhibits, and networking were geared toward nurses, pharmacists, and physicians who are on the front lines of treating myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, common variable immunodeficiency, primary immune thrombocytopenia, immunologic recurrent pregnancy loss, dermatomyositis, polymyositis, and juvenile dermatomyositis, plus other conditions.

Click above for our post-conference wrap-up report.